China’s negative population growth leads to discussions on supporting assisted reproductive technologies (ART)

http://en.people.cn/n3/2024/0304/c90000-20140206.html

Recent data released by the National Bureau of Statistics (NBS) show that China’s population decreased by 2.08 million people in 2023 to 1.40967 billion. In 2023, 9.02 million babies were born, resulting in a birth rate of 6.39 per thousand people. The birth rate marks a historic low in nearly 74 years (since 1950), and the population has experienced two consecutive years of negative growth, with a total fertility rate of around 1.0, significantly lower than the average total fertility rate of other major countries  during the same period, ranging from 1.47 to 1.65. The proportion of infertility in China has increased from 1 to 2 percent in the 1970s to 12.5 to 15 percent three decades later, marking a nearly tenfold increase over 30 years. According to statistics, in 2023, the incidence of infertility in China has risen to 18 percent, with approximately 1 in every 5 to 6 couples experiencing difficulties with conception. This means that over 50 million couples nationwide are affected by infertility issues

As a result, some provinces and cities in China have included assisted reproductive technologies (ART) in their medical insurance as part of supportive policies to encourage childbirth, and political advisors suggest including as many ART procedures as possible in the national medical insurance reimbursement scope, including artificial insemination, embryo transplantation, and sperm selection. Furthermore, exploring the feasibility of egg-freezing for single women could also be considered at an appropriate time.

Due to changes in attitudes toward marriage and childbirth, some single women are beginning to freeze their eggs as a means of postponing reproduction, preserving fertility, and asserting their reproductive rights. However, issues related to technology, law, ethics, and others remain unresolved,

China’s negative population growth leads to discussions on supporting assisted reproductive technologies (ART)
Scroll to top